Introduction
Liver transplantation, like all solid organ transplantation, is characterized by progressive disparity between supply and demand, with ever increasing numbers of potential candidates and a significantly slower rise in the number of donor organs available. Despite using organs from older donors and donors with steatosis or evidence of current (e.g. hepatitis C positive) or prior (e.g. hepatitis B core antibody positive) viral hepatitis, the number of deceased donor organs has increased slowly. This shortage led to a marked increase in adult-to-adult living donor transplantation from 1998 to 2001. Although this trend was expected to continue to grow as it has in renal transplantation, a marked decrease in adult living donor transplants was seen in 2002, with the number of procedures decreasing by approximately 50% back to the level seen in 2000 (1) . This trend probably reflects concerns about donor safety among programs, potential donors, and recipients following highly publicized adverse donor outcomes. Additionally, after several years the majority of patients on existing transplant waiting lists who were interested in and prepared for living donor transplantation had already undergone the procedure, thus leaving primarily the smaller pool of new listings as potential living donor candidates.
Given the decrease in living donor transplants and a more limited applicability of this modality than for renal transplantation, the need to maximize the utility of deceased donor organs is paramount. In response to the HHS final rule and the Institute of Medicine Report, the model for end-stage liver disease and pediatric end-stage liver disease (MELD and PELD) scores for prioritization of adult and pediatric liver transplant candidates were implemented to replace the prior allocation scheme with an objective severity-based allocation model. Initially designed to predict post-TIPS mortality, MELD was shown to be superior to Child-Pugh classification at predicting short-term patient mortality in diverse patient groups with end-stage liver disease, including transplant candidates. The system was fully implemented at the end of March 2002, making 2002 the first year to assess the impact of using the new allocation system. This report contains the first significant data using MELD/PELD, the implementation of which has resulted in decreased pretransplant mortality and some important shifts in which patients, particularly those with hepatocellular carcinoma, receive transplants. MELD and PELD are also addressed in a companion article in this report, 'Improving liver allocation: MELD and PELD' (2) . Waiting list mortality, however, remains significant and has grown over the last decade while post-transplant survival has improved, making the survival benefit of transplant compared to waiting even greater.
Intestine transplantation remains a lower-volume procedure limited to a small number of centers and still accompanied by high rates of death on the transplant waiting list and high rates of graft failure and death post-transplantation. It is hoped that continued advances in patient and donor selection, as well as in immunosuppressive and perhaps immune tolerance protocols, will continue the advances in this field over the coming years.
Unless otherwise noted, the statistics in this article come from reference tables in the 2003 OPTN/SRTR Annual Report. Two companion articles in this report, 'Transplant data: sources, collection, and caveats' and 'Analytical approaches for transplant research', explain the methods of data collection, organization, and analysis that serve as the basis for this article (3, 4) . Additional detail on the methods of analysis may be found in the reference tables themselves or in the Technical Notes of the OPTN/SRTR Annual Report, both available online at http://www.ustransplant.org.
Liver Transplantation
Liver waiting list characteristics As in other fields of solid organ transplantation, the gap between the number of patients listed as candidates for liver transplantation and the number of transplants performed has grown over the last 10 years livers and split livers, both of which have increased rates of graft failure when compared to standard grafts (5-7).
Overall, the waiting time for liver transplantation continues to increase ( Figure 3 MELD scores above 30 made up 0.6% of the total waiting list. The pediatric patients on the waiting list had a similar distribution, but more patients waiting were in the lower PELD bracket; 77% of pediatric patients had a PELD score of less than 11, 15% had a PELD score of 11-20, 6% had a PELD score of 21-30 and only 2% had a PELD score above As mentioned above, patients registered for liver transplantation showed a distribution of blood types in which type O candidates were more common on the waiting list than in the US general population. Access to transplantation was better for type AB. The median waiting time for liver transplantation for type AB was 136 days. discussed in detail in the MELD/PELD article in this report (2) . In addition to a drop in the absolute number of deaths on the liver waiting list, the rate of death continues to decline, reflecting either continued improvements in pretransplant care or a continued increase in the number of patients on the waiting list with low short-term mortality risk ( Figure 6 ). Although the MELD/PELD system did not alter the allocation system for Status 1 patients, the mortality rate continued to fall for this group as well in 2002. The decline in mortality rate for Status 1 patients occurred despite an increase in the median time to transplant ( Figure 7 ). This suggests that the continued downward trend in waiting list mortality may be related, in part, to improvements in pretransplant care as well as to improved access to livers for those with an urgent need for transplantation. Deaths on the pediatric waiting list have been very low, reflecting the intended design of the system, which predicts lower mortality risk at any given PELD score compared with the equivalent MELD score.
Another important waiting list trend is the dramatic decline Again, this is probably an effect of the MELD allocation system, because patients who are listed when they are very ill no longer have to accrue substantial waiting time before being allocated a liver, and patients are no longer being listed simply to accrue waiting time. In 2002, the annual death rate per 1000 patient years at risk was highest for African-Americans (153), followed by whites (103), then Asians (84). Hispanics had 113 deaths per 1000 patient years at risk. There was no difference in death rates between female and male patients on the waiting list (101 and 109, respectively). The annual death rates per 1000 patient years at risk varied minimally by blood type: 108 for type O, 100 for type A, 119 for type B and 95 for type AB.
The annual death rate per 1000 patient years at risk was higher in patient groups with higher MELD scores, as expected. The annual death rates per 1000 patient years at risk in 2002 were 52 in patients with MELD scores of 6-10, 121 in patients with scores of 11-20, 666 in patients with scores of 21-30, and 3029 for patients with MELD scores of 30 and above. This has been seen despite the fact that the waiting time for transplant was much shorter in the higher MELD score groups and reflects the ability of MELD to predict short-term mortality accurately. The risk of death on the waiting list by MELD still varies by region and blood type. Although organ distribution issues remain controversial, future research is needed to attempt to equalize the risk of dying on the waiting list. Recipient race was 83% white, 10% African-American, 4% Asian, and 3% other/multiracial. These percentages are similar to the characteristics of the waiting list patients, of whom 87% were white, 7% African-American, 4% Asian, and 2% other/multiracial ( Figure 9 ). Ethnicity was similar between the waiting list patients and transplant recipients for the Hispanic/Latino population (15% and 13%, respectively) and for the non-Hispanic/non-Latino population (84% and 87%, respectively). The percentage of white recipients decreased from 86% in 1993 to 83% in 2002, with a concurrent rise in African-American recipients from 8.7% to 9.6% and in Asians from 2.6% to 4.3%. The proportion of patients of Hispanic ethnicity increased from 10% to 13%. There continued to be a trend towards a greater percentage of men being transplanted (66% in 2002); this may reflect the distribution of diseases between men and women, disease severity, and size considerations. The blood type distribution for recipients in 2002 was type O 42%, type A 39%, type B 13%, and type AB 6%. This matches the overall estimates of blood types in the US population (and thus the donor population) and has not changed since 1993. The percentage of blood type O among recipients is lower than that of the patients waiting for transplantation. Approximately 9% of liver transplant recipients in 2002 had undergone a prior liver transplant, the lowest percentage to date, down from 17% in 1993 and 10% in 2001. The absolute number of retransplantation procedures was 571 in 1993 and has since remained between 425 and 467 per year. US residents made up 99% of the recipients.
The MELD/PELD system of recipient prioritization was implemented on February 27, 2002, so that data from 2002 includes transplant recipients transplanted under the MELD/PELD system (n = 3830, or 77%) and the old Status 2, 2A, 2B, 3, and 7 system (n = 652, or 13%). The Status 1 system was unaffected by MELD/PELD, and 480 (10%) Status 1 patients were transplanted in 2002, compared with 601 in 2001. In 2002, 'not hospitalized', 'hospitalized', and 'in intensive care unit' (ICU) recipients made up 69%, 15%, and 15%, of the total, respectively, with the most substantial change being a decrease in the ICU-bound recipients from 27% in 2001 to 15% in 2002 (a relatively steady decrease over the past decade). Only 7% of recipients were on life support at transplant, compared with 11% in 2001. One of the anticipated benefits of the MELD/PELD system is that sicker patients will be transplanted before they progress to a more grave ICU-bound status. This was seen in New England, where implementation of a point system based on disease severity prior to MELD/PELD resulted in the sicker 2B patients being transplanted before they progressed to 2A (9) . Of note was the increase in the 'not hospitalized' recipients, from 58% in 2001 to 69% in 2002. This trend is probably multifactorial, resulting from a higher percentage of stable hepatocellular carcinoma patients transplanted after implementation of the MELD/PELD system, decreased severity of illness due to pre-emptive transplantation, improved pretransplant care, and decreased use of the ICU to maintain patient medical urgency status. Whether these trends will continue remains to be seen. The MELD scores at which adult recipients received transplants in 2002 included the following percentages: 6-10 (4%), 11-20 (24%), 21-30 (15%), and >30 (10%). The PELD scores for children included the follow- (34%) , possibly because of size considerations. A greater proportion of living donor recipients were blood type O (55%) compared with deceased donors (42%), probably reflecting the markedly longer waiting times for deceased donor organs among blood type O candidates and a tendency, therefore, to opt for living donor transplantation. Only 2% of recipients were retransplants, and 2% were nonUS residents. There was a trend towards living donor recipients being less ill: 79% were not hospitalized compared with 69% for deceased donor recipients, and only 8% were in an ICU compared with 15% of deceased donor recipients. Similarly, the MELD scores for the adult recipients were lower: 6-10 (14%), 11-20 (41%), 21-30 (3.9%). Furthermore, fewer patients were transplanted for hepatocellular carcinoma (1.4% T1 and 0.8% T2), probably due to the increased points received by HCC patients after the implementation of the MELD system. PELD scores for pediatric living donor recipients were: <11 (5%), 11-20 (3%), 21-30 (2%), and >30 (0.3%). The primary diagnoses were similar to deceased donor recipients except for a slight trend towards more cholestatic disease/cirrhosis and fewer ma- lignant neoplasms in the living donor recipients. Parents made up 15% of donors, offspring 25%, siblings 20%, other relatives 10%, spouse 5%, and other unrelated 17% ( Figure 11 ). The increase in unrelated donors has occurred since the introduction of adult-to-adult living donor liver transplant despite the risks to the donors. This increase undoubtedly reflects the tremendous pressures that the shortage of deceased donor livers and long waiting times are putting on patients and their friends and relatives.
Liver transplant patient survival
Unadjusted patient survival among deceased donor liver transplant recipients was 92% at 3 months, 86% at 1 year, 78% at 3 years, and 72% at 5 years post-transplant. Among living donor transplant recipients, unadjusted survival was slightly higher at all time points except 3 years post-transplant ( Figure 12 ). Differences in unadjusted patient survival between groups of patients at each time period were significant at p ≤ 0.05 for comparisons based on race, whether the patient was on life support, ICU Patient survival for deceased donor recipients varied significantly with recipient age. Five-year survival was 84% in the 6-10 year old group but only 62% in recipients over 65 years of age. African-American patient survival was 2-5% lower than that of whites at each of the time intervals. Patient survival was similar by ethnicity and gender. Patients transplanted from the ICU had a lower post-transplant survival when compared with patients who came in from home, a difference seen in both short-term and long-term survival. The difference in survival was 7% at 3 months, 9% at 1 year, 11% at 3 years, and 9% at 5 years. Patients on life support before transplantation had an 80% survival at 3 months and 63% at 5 years, which was 13% and 10% lower, respectively, than for those who were not on life support (p < 0.0001).
Patient survival also varied based on etiology of liver disease ( Figure 13 ). Five-year patient survival was worst for malignancy (59%). Acute hepatic necrosis (69%) and noncholestatic liver diseases (70%) were an intermediate group. The best survival rates were seen with metabolic liver disease (80%), biliary atresia (80%), and cholestatic liver disease (81%). These differences are related to two factors: (i) severity and recurrence of disease and (ii) age differences in the recipients.
The volume of liver transplants performed per center did not influence the unadjusted patient survival at all time intervals to 5 years post-transplant. Donor age above 65 years was associated with a lower patient survival (90% at 3 months, 61% at 5 years). age. In 2002, the annual death rate per 1000 patient years at risk in the first year post-transplant was 279 in infants under 1 year of age, a marked reduction from the corresponding figure in 1993 (1060), and was 181 in patients older than 65 years.
The annual death rate per 1000 patient years at risk in the first year post-transplant was moderately different by ethnicity and race: 128 for Hispanics, 145 for whites, 146 for African-Americans, and 164 for Asians. African-American patient survival was 2-5% lower than that of whites at each of the time intervals (p < 0.05 for each year). The risk of death post-transplant was also similar among different blood types. The risk almost tripled if the recipient had any previous solid organ transplant (337 vs. 130 after primary transplants).
In 2002, for the first year following transplant, recipients who underwent transplant from the ICU had an annual death rate per 1000 patient years that was 2.5 times higher than that of patients who came from home. In 1993, the corresponding difference in death rate between patients receiving transplant from the ICU vs. from home was 3.1.
The overall risk for patients in the ICU has decreased by 54%, from 485 in 1993 to 263 in 2002. Similarly, patients on life support before transplant had a threefold higher annual death rate per 1000 patient years at risk in the first year than those who were not. Despite the improvements in care seen over the last decade, the higher risk of death experienced by patients on life support has changed little over the decade.
In 2002, the annual death rate per 1000 patient years at risk in the first year post-transplant was highest for patients with acute hepatic necrosis (229) and malignancy (203), followed by those with noncholestatic liver diseases (143), cholestatic liver diseases (96), metabolic liver diseases (77), and biliary atresia (74). This raises the question as to whether most malignancies are recurring early post-transplant.
There 
Liver transplant graft survival
Graft survival after deceased donor liver transplantation was 87% at 3 months, 81% at 1 year, 72% at 3 years, and 64% at 5 years post-transplant. Unadjusted living donor recipient graft survival was slightly lower at all time points except 5 years post-transplant (Figure 14) . The 1-year adjusted deceased donor recipient graft survival increased from 72% in 1992 to 81% in 2001. African-Americans tended to have worse graft survival than the white patient population. The gap has been 2-6% each year and has tended to increase. There was no difference in graft survival between Hispanics and non-Hispanics or between male and female patients.
Notably, patients with blood type AB had graft survival 4-6% higher than the patients with other blood types at the 3-month interval. Patients who underwent retransplantation had 18-21% lower graft survival than those who underwent primary transplantation.
In terms of severity of illness, there was a difference in graft survival among patients who came to transplant from home, those who were in the hospital, and those who were in the ICU. Patients who were in the ICU had 12-14% worse graft survival than those who came from home. Three-month graft survival was 79% for patients transplanted from the ICU and 91% for those who came from home. This difference was maintained over time; 5-year graft survival rates were 56% and 69%, respectively. Donor age was also associated with differing effects on graft survival, especially at the extremes of age. For donors younger than 1 year, 3-month graft survival was 77% and 5-year graft survival was 61%. The best graft survival was seen with donors aged 11-17 years (89% and 70%, respectively). Among donors of adult age, graft survival declined as age increased. Graft survival was 82% at 3 months and 51% at 5 years post-transplant using organs from donors aged 65 years or older. These graft survival statistics by donor age are not adjusted for other factors, therefore the potential confounding effects of various recipient selection factors are not apparent. However, the separate results by donor age and recipient disease severity highlight the increased risk of placing the most marginal grafts (e.g. from donors older than 60 years) into ICU-bound patients on life support. Differences in unadjusted graft survival between groups of patients at each time period were significant at p ≤ 0.05 for comparisons based on race, medical condition, blood type, retransplantation status, and donor age. 
Prevalence of liver transplant patients with functioning grafts
Given the overall success of liver transplantation, the prevalence of people living with a functioning liver graft in the USA increased gradually from 10 141 in 1993 to 31 195 in 2002 ( Figure 15 ). In 2002, 27 138 were white, 2532 were African-American, and 981 were Asian. The prevalence of patients with functioning grafts allows one to study trends over time for both incidence and outcome, although the figures are more heavily weighted towards recent transplants, because a higher proportion of recent transplant recipients will be alive.
The proportion of patients with functioning liver transplants who were African-American increased from 7.7% in 1993 to 8.1% in 2002, Asians increased from 2.1% to 3.1% and whites decreased from 88.7% to 87.0%. The Hispanic proportion increased from 9% to 11%. This probably reflects improved access to transplantation over time, rather than improved outcomes in these racial and ethnic groups. Among patients living with a liver graft, 59% were male and 41% were female. Blood type distribution was similar to the general population, which reflects the donor blood type distribution and not the distribution on the waiting list.
At the end of 2002, a total of 29 859 recipients of deceased donor grafts were living, as were 1336 recipients of living donor grafts. Among patients with a functioning graft, 57% had been transplanted for noncholestatic liver disease, 15% for cholestatic liver disease, 8% for acute hepatic necrosis, 6% for biliary atresia, 5% for metabolic disease, and 3% for malignancy. Living retransplant recipients accounted for 8% of the total.
Distribution by medical urgency status at transplant was as expected, given the relative rates of these transplants and their relative survival; 63% came to transplant from home, 18% were in hospital, and another 19% were in the ICU. For these patients, 9% had been on life support before transplant and 3934 patients (13%) had been transplanted as Status 1.
Intestine
Intestinal failure, due either to loss or nonfunction of the gastrointestinal tract, can be a pernicious disorder often resulting in disability or death of the patient. Intestinal transplantation was proposed as a treatment for those patients who had life-threatening complications of total parenteral nutrition (TPN), particularly TPN-related liver disease. During the past 15 years, organ replacement therapy in the form of liver, liver/small bowel, and isolated small bowel transplantation has been used as a lifesaving tool for patients who have failed TPN therapy.
Approval by the Centers for Medicare and Medicaid Services (CMS) for reimbursement of intestinal transplantation was the most important governmental change in the field of intestinal transplantation in 2002. CMS approval is often the yardstick that third party payers use to determine if a new procedure is investigational or experimental. One of the major obstacles to access to intestinal transplantation has been financial. While some commercial carriers were providing this service to their policy holders, many carriers and state Medicaid agencies were not. As a consequence of the CMS findings, more patients were provided an opportunity to be considered for intestinal transplantation. There were no major OPTN policy changes in 2002 regarding this procedure, but the stage had been set for changes to occur in 2003. Specifically, efforts were being made to provide extra MELD/PELD points to patients with intestinal failure. In 2003, the OPTN approved a policy change that encouraged regional review boards to allow patients on the waiting list for combined liver/small bowel transplant to receive an extra 12 MELD/PELD points. 2004 will probably see further developments in this area.
Intestine waiting list characteristics
The number of patients listed for intestinal transplantation has gradually increased since 1993, with the exception of a 9% reduction in patient registrations in 2002. At the end of 2002, however, there were more patients listed for intestinal transplant compared with 2001 ( Figure 16 ). The age of the patients awaiting intestinal transplants was weighted heavily toward children (73%). Children less than 6 years of age represented 51% of the list. Race and ethnicity were characterized predominately as white and nonHispanic/non-Latino, respectively. There were many more males than females listed, and the predominant blood type was O. Prior transplant had been performed in 9% of patients, with the majority having undergone prior intestinal transplantation (7%).
Intestine time to transplant
Nearly one-third of patients awaiting intestinal transplants have waited longer than 2 years, and two-thirds have (Figure 17 ). Children tended to have longer waiting times than adults. The median time to transplant based on race did not differ among white, Asian and other/multirace candidates. Follow-up was insufficient to evaluate the AfricanAmerican and Hispanic/Latino groups. Neither prior transplant nor blood type appeared to have a major effect on waiting time. The only exception to this was blood type AB, which had a median time to transplant of only 44 days.
Intestine waiting list deaths
Reported deaths and annual death rates per 1000 patient years at risk have fluctuated over the past 10 years (Figure 18 ). In 2002, there were 363 patients at risk for death on the waiting list; this was a modest increase from 342 in 2001 and a sixfold increase from the 58 patients at risk in 1993. The death rate for all patients waiting for intestinal transplants in 2002 was 298. This rate is much higher than that of any other transplant group (e.g. heartlung is 185). Despite considerable variability over the years, the age group at greatest risk comprises those patients younger than 1 year. Factors that contribute to this high number include the need for size compatible donor organs (typically 25% smaller) and donor cytomegalovirus serologic status. A review of other demographic factors, such as race, ethnicity, and gender, has failed to demonstrate any differences. Blood type B did have an apparent effect, with a reported death rate of over 500 compared with 251 and 267 for blood types O and A, respectively. Currently efforts are being made to change organ allocation policy to improve candidates' opportunity to receive intestine transplants. A number of other variables can affect the post-transplant death rates, including condition of the patient, underlying diagnosis, and donor age. The condition of the patient was categorized into one of three groups: on life support, in the ICU, or hospitalized/at home. The numbers of patients on life support were too small to calculate an annual death rate. In 2000, however, patients transplanted from the intensive care unit had a threefold higher death rate compared with patients on a general ward in the hospital, and an almost twelvefold higher death rate when compared with patients coming from home. The primary diagnosis had a modest effect on survival, with short gut syndrome associated with about a 40% lower death rate when compared with patients with functional bowel problems. Donor age demonstrated wide variability within the various age groups examined.
Intestine transplant recipient characteristics

Intestine transplantation-graft survival and function
Adjusted graft survival was determined at four time points following transplantation: 3 months, 1 year, 3 years, and 5 years. Sixty-four per cent of patients had a functioning allograft at 1 year, but this number was only 33% at 5 years ( Figure 19 ). No obvious trends could be seen by age group, race, gender or primary diagnosis. This reflects the small number of patients in the various groups. Patients who underwent retransplantation had by far the worst outcome. Neither center volume nor donor age had a major effect on graft survival.
All organ replacement therapies seek first to save patient lives but also to provide organs that function adequately. For intestinal transplantation, adequate function would be represented by freedom from TPN. As of 2002 there were 299 patients with functioning intestinal allograft. Children aged 1-5 years represented the largest group (31%) with a functioning allograft. No long-term effect on graft function could be seen based on pretransplant diagnosis.
Intestine transplant patient survival
Patient survival rates at 3 months, 1 year, 3 years, and 5 years following intestine transplantation were 85%, 74%, 59%, and 50%, respectively (Figure 19 ). The very young and very old appeared to fair worse in both short-and long-term follow-up. The greatest success was achieved in the 18-34 year age range in adjusted survival, a difference not found in the unadjusted analysis. Where adequate data were available, no major differences could be seen based gender or ethnicity. Racial differences were evident between whites and African-Americans at all time points. Recipient blood type did not influence survival in the short term, but some differences did appear at the 5-year mark. Blood type B had the best survival, while blood type AB fared the worst, although the limited number of patients makes this finding difficult to interpret. Primary diagnosis had no effect on patient survival, whereas the retransplant group was poorly represented and no data were available. A negative center effect could only be seen in programs that performed only one transplant per year.
Summary
The most significant development in liver transplantation in the USA over the past year was the full implementation of MELD-and PELD-based allocation, which has shifted emphasis from waiting time within broad medical urgency status to one based on prioritization by risk of waiting list death. The implementation of this system has led to a decrease in pretransplant mortality without increasing posttransplant mortality, despite a higher severity of illness at the time of transplant. Over the next few years, the focus will shift to refining and improving the model to limit the need for exception and regional review boards, as well as addressing disparities in organ distribution and incorporating post-transplant outcomes. The trend over the last few years of rapidly increasing numbers of living donor transplants has stabilized or declined, with a reduction in these procedures in adults in 2002. Living donor transplants account for less than 10% of all liver transplants, in contrast to kidney transplantation in which the number of living donor and deceased donor grafts are nearly matched. Concerns about living donor safety, early graft survival, and, at present, limited applicability to critically ill patients has decreased the use of this procedure. It is hoped that new data showing the benefit of living donor liver transplantation on waiting list mortality, along with further refinement in donor and recipient selection, will allow ongoing growth of this procedure and added benefit for all patients awaiting liver transplantation (13) . Intestinal transplantation remains a low-volume procedure limited to a few transplant centers, and like liver transplantation in its early days, it is still fraught with both pre-and post-transplant risks. As this procedure matures, its application will probably increase to include recipients at an earlier stage of disease and with better likelihood of success.
